CytRx Corporation (CYTR) Shares are Down -5.09%

CytRx Corporation (CYTR) : During the past 4 weeks, traders have been relatively bearish on CytRx Corporation (CYTR), hence the stock is down -5.69% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -5.57% relative to the S&P 500. The 4-week change in the price of the stock is -5.81% and the stock has fallen -5.09% in the past 1 week.

The stock has recorded a 20-day Moving Average of 1.94% and the 50-Day Moving Average is 44.23%.The 200 Day SMA reached 74.22%. CytRx Corporation has dropped 79.04% during the last 3-month period . Year-to-Date the stock performance stands at -78.48%.


CytRx Corporation (NASDAQ:CYTR): The stock opened in the green at $0.579 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $0.587 and a low of $0.566 for the day. The stock did not find buyers even at the lows and closed at $0.5702 recording a loss of -1.43%. 889,896 shares exchanged hands during the trading day. The stock had closed at $0.5785 in the previous days trading.

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company is focused on the clinical development of aldoxorubicin, its modified version of a chemotherapeutic agent. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. It consists of (6-Maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. Its laboratory in Freiburg, Germany is conducting discovery and translational research to create drug candidates that utilize linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.